Compare National Beverage Corp. (FIZZ) vs Hims and Hers Health Inc (HIMS) Price & Performance

FIZZ trades at $31.47, up 1.78% today, but faces bearish technical signals with three consecutive earnings misses. The company maintains solid profitability with 15.56% net margins and 34.03% ROE, though revenue growth has stalled at $1.2B annually. Recent news highlights a $3.25 special dividend announcement but also concerns about LaCroix brand decline and muted growth prospects.

The outlook remains cautious with analyst sentiment skewed bearish (50% sell ratings) and technical indicators pointing downward. While the dividend provides shareholder return, fundamental challenges including competitive pressures and stagnant revenue create headwinds for meaningful price appreciation in the near term.

Hims & Hers Health trades at $35.52, up 1.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $33.57. Recent earnings show volatility with a Q1 2026 miss, but revenue grew to $2.35 billion in 2025. The company benefits from expansion in weight-loss therapies and a $400 million JPMorgan facility, though high valuations like a P/E of 57.14 and negative net income margin pose concerns.

Outlook is mixed: growth opportunities in telehealth and GLP-1 drugs support upside, but earnings inconsistency and regulatory risks from FDA reviews require caution. Analysts are 35% buy-rated, highlighting potential if execution improves, yet investors face volatility near key resistance at $38.